Roche (RHHBY)'s New MS Drug "Cuts Relapses by 80 Percent" in Phase 2 Trial
11/2/2011 8:10:48 AM
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men. The study, carried out by researchers at UCSF Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British medical journal The Lancet.
comments powered by